Economic evaluation of repeat universal antenatal screening for HIV in the third trimester of pregnancy
Flattery M, Harrington P, O'Neill M, Teljeur C, Ryan M
Record ID 32013000675
English
Authors' recommendations:
This economic evaluation examined the additional costs and health benefits associated with the introduction of repeat universal antenatal screening for HIV in the third trimester, together with the budget impact of such a policy. Based on the model assumptions and input parameters, over a 1-year period, in the absence of repeat universal antenatal screening for HIV in the 3rd trimester in Ireland, 5 infants will be exposed to HIV and 1 of these infants will become HIV-positive. Introduction of repeat universal antenatal screening for HIV in the 3rd trimester will, on average, prevent 1 infection a year with the estimated discounted life years gained being 14.4 years. The median ICER is €66,278 (95% CI: €42,369 –€101,089) per life year gained. Arising from the findings listed above, the cost of introducing repeat universal antenatal HIV screening in the 3rd trimester is high compared to the expected benefits. In the context of a finite healthcare budget, consideration must be given to the existing services that may need to be displaced should a decision be made to introduce repeat testing at a cost of €1.25 million per annum.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.hiqa.ie/publications/economic-evaluation-repeat-universal-antenatal-screening-hiv-third-trimester-pregnancy
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Ireland
MeSH Terms
- Humans
- Mass Screening
- Cost-Benefit Analysis
- HIV Infections
- Pregnancy
- Pregnancy Complications, Infectious
- Prenatal Diagnosis
- Infectious Disease Transmission, Vertical
- Ireland
Contact
Organisation Name:
Health Information and Quality Authority (HIQA)
Contact Address:
Health Information and Quality Authority, George's Court, George's Lane,Smithfield, Dublin 7. PH : + 353 (01) 814 7464
Contact Name:
info@hiqa.ie
Contact Email:
info@hiqa.ie
Copyright:
Health Information and Quality Authority
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.